



## **Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences**

CONSHOHOCKEN, Pa., June 4, 2019 -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Paul Friedman, M.D., Chief Executive Officer of Madrigal, and Becky Taub, M.D., CMO and Executive VP, Research & Development of Madrigal will present at the following conferences in June 2019:

**Jefferies 2019 Healthcare Conference** – New York

Thursday - June 6, 2019, 10:00 AM ET

**Goldman Sachs 40th Annual Global Healthcare Conference** - Rancho Palos Verdes, CA,

Wednesday, June 12, 2019, 11:20 AM PT

**JMP Securities Life Sciences Conference** – New York

Wednesday, June 19, 2019, 3:30 PM ET

Live webcasts of the presentations can be accessed through the Investors section of the Madrigal website at <https://www.madrigalpharma.com>

A replay of the webcasts will be available for 90 days following the live presentations.

### **About Madrigal Pharmaceuticals**

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal's lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)- $\beta$  selective agonist.

For more information, please visit [www.madrigalpharma.com](http://www.madrigalpharma.com).

### **Investor Contact:**

Marc Schneebaum, Madrigal Pharmaceuticals, Inc. [IR@madrigalpharma.com](mailto:IR@madrigalpharma.com)

### **Media Contact:**

Mike Beyer, Sam Brown Inc. [mikebeyer@sambrown.com](mailto:mikebeyer@sambrown.com) 312 961 2502